NASDAQ:NGM
NGM Biopharmaceuticals Inc. Stock News
$1.54
+0 (+0%)
At Close: May 17, 2024
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Should You Buy?
04:48pm, Wednesday, 04'th Aug 2021
NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NGM Biopharma, Merck Amend Development Pact To Focus On Retinal, Cardiovascular & Metabolic Targets
01:50pm, Thursday, 01'st Jul 2021
NGM Biopharmaceuticals Inc (NASDAQ: NGM) has amended and restated an agreement with Merck & Co Inc (NYSE: MRK) to extend their ongoing collaboration through March 2024 with a narrower scope. Th
SOUTH SAN FRANCISCO, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) today announced that the company has entered into an amended and restated agreement with Merck, known
NGM Biopharmaceuticals (NGM) Stock Jumps 7%: Will It Continue to Soar?
09:01am, Thursday, 03'rd Jun 2021
NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mo
Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM B
Los Angeles, California--(Newsfile Corp. - June 1, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM B
Los Angeles, California--(Newsfile Corp. - May 31, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM B
Los Angeles, California--(Newsfile Corp. - May 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM B
Los Angeles, California--(Newsfile Corp. - May 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM B
LOS ANGELES, May 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NGM Biopharmaceutical
Why NGM Biopharmaceuticals Dived by 41% on Monday
06:19pm, Monday, 24'th May 2021
The results of a hepatitis drug candidate's clinical trial were not good.
LOS ANGELES--(BUSINESS WIRE)---- $NGM #NGM--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against NGM Biopharmaceuticals, Inc.
Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
02:39pm, Monday, 24'th May 2021
Today, NGM Biopharmaceuticals Inc (NASDAQ: NGM) reported disappointing results from the Phase 3 trial of aldafermin in NASH patients. What Happened: The primary endpoint of an improvement in fibro
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
12:53pm, Monday, 24'th May 2021
Scopus BioPharma Inc. (NASDAQ: SCPS), NGM Biopharmaceuticals, Inc. (NASDAQ: NGM) and Taiwan Liposome Company, Ltd. (NASDAQ: TLC) are among the biggest biopharma movers Monday.
NGM Stock Price: Over 40% Decrease Pre-Market Explanation
09:11am, Monday, 24'th May 2021
The stock price of NGM Biopharmaceuticals Inc (NASDAQ: NGM) decreased by over 40% pre-market. This is why it happened.
